Hereditary Syndromes with Signs of Premature Aging.
Journal
Deutsches Arzteblatt international
ISSN: 1866-0452
Titre abrégé: Dtsch Arztebl Int
Pays: Germany
ID NLM: 101475967
Informations de publication
Date de publication:
22 07 2019
22 07 2019
Historique:
received:
19
11
2018
revised:
19
11
2018
accepted:
13
05
2019
entrez:
28
8
2019
pubmed:
28
8
2019
medline:
7
7
2020
Statut:
ppublish
Résumé
Segmental progeroid syndromes (SPS) are rare hereditary diseases in which the affected individuals show signs of premature aging in more than one organ or type of tissue. We review the clinical and genetic features of some of these syndromes and discuss the extent to which their study affords a complementary opportunity to study aging processes in general. This review is based on publications retrieved by a selective search in PubMed. Segmental progeroid syndromes are a clinically and genetically heterogeneous group of hereditary diseases. They can be categorized, for example, by the age of onset of manifestations (congenital vs. infantile vs. juvenile/adult forms). They are diagnosed on clinical grounds supplemented by genetic testing on the basis of next-generation sequencing, which is of central importance in view of the marked heterogeneity and complexity of their overlapping clinical features. The elucidation of the genetic and molecular causes of these diseases can lead to causally directed treatment, as shown by the initial clinical trials in Hutchinson- Gilford progeria syndrome. The molecular features of SPS are identical in many ways to those of "physiological" aging. Thus, studying the molecular mechanisms of SPS may be helpful for the development of molecularly defined treatment approaches for age-associated diseases in general. Segmental progeroid syndromes are a complex group of diseases with overlapping clinical features. Current research efforts focus on the elucidation of the molecular mechanisms of these diseases, most of which are very rare. This should enable the development of treatments that might be applicable to general processes of aging as well.
Sections du résumé
BACKGROUND
Segmental progeroid syndromes (SPS) are rare hereditary diseases in which the affected individuals show signs of premature aging in more than one organ or type of tissue. We review the clinical and genetic features of some of these syndromes and discuss the extent to which their study affords a complementary opportunity to study aging processes in general.
METHODS
This review is based on publications retrieved by a selective search in PubMed.
RESULTS
Segmental progeroid syndromes are a clinically and genetically heterogeneous group of hereditary diseases. They can be categorized, for example, by the age of onset of manifestations (congenital vs. infantile vs. juvenile/adult forms). They are diagnosed on clinical grounds supplemented by genetic testing on the basis of next-generation sequencing, which is of central importance in view of the marked heterogeneity and complexity of their overlapping clinical features. The elucidation of the genetic and molecular causes of these diseases can lead to causally directed treatment, as shown by the initial clinical trials in Hutchinson- Gilford progeria syndrome. The molecular features of SPS are identical in many ways to those of "physiological" aging. Thus, studying the molecular mechanisms of SPS may be helpful for the development of molecularly defined treatment approaches for age-associated diseases in general.
CONCLUSION
Segmental progeroid syndromes are a complex group of diseases with overlapping clinical features. Current research efforts focus on the elucidation of the molecular mechanisms of these diseases, most of which are very rare. This should enable the development of treatments that might be applicable to general processes of aging as well.
Identifiants
pubmed: 31452499
pii: arztebl.2019.0489
doi: 10.3238/arztebl.2019.0489
pmc: PMC6726857
doi:
pii:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
489-496Références
Am J Med Genet A. 2014 Oct;164A(10):2510-3
pubmed: 24989684
Nat Genet. 2013 Feb;45(2):136-44
pubmed: 23263490
PLoS One. 2007 Dec 05;2(12):e1269
pubmed: 18060063
Cell. 2013 Jun 6;153(6):1194-217
pubmed: 23746838
Aging (Albany NY). 2017 Apr;9(4):1143-1152
pubmed: 28377537
Nature. 2003 May 15;423(6937):293-8
pubmed: 12714972
Cell. 2014 Jan 30;156(3):400-7
pubmed: 24485450
Dis Model Mech. 2016 Jul 1;9(7):719-35
pubmed: 27482812
Hum Genet. 2018 Dec;137(11-12):921-939
pubmed: 30450527
Cell. 2005 Feb 25;120(4):523-32
pubmed: 15734684
EBioMedicine. 2019 Feb;40:554-563
pubmed: 30616998
Eur J Hum Genet. 2016 Aug;24(9):1244-7
pubmed: 26860060
Am J Med Genet A. 2016 Dec;170(12):3343-3346
pubmed: 27612211
Am J Med Genet A. 2011 Dec;155A(12):3002-6
pubmed: 22065502
Aging Cell. 2015 Aug;14(4):644-58
pubmed: 25754370
Science. 2004 Sep 3;305(5689):1426-31
pubmed: 15353794
JAMA. 2018 Apr 24;319(16):1687-1695
pubmed: 29710166
Dtsch Arztebl Int. 2019 Mar 22;116(12):197-204
pubmed: 31056085
J Clin Invest. 2017 Oct 2;127(10):3598-3608
pubmed: 28846075
Am J Hum Genet. 2019 Apr 4;104(4):749-757
pubmed: 30905398
Science. 2006 May 19;312(5776):1059-63
pubmed: 16645051
Proc Natl Acad Sci U S A. 2012 Oct 9;109(41):16666-71
pubmed: 23012407
Nat Genet. 2014 Nov;46(11):1239-44
pubmed: 25261934
Am J Hum Genet. 2018 Dec 6;103(6):968-975
pubmed: 30414627
Am J Hum Genet. 2011 May 13;88(5):650-6
pubmed: 21549337
Am J Med Genet A. 2017 Jul;173(7):1763-1772
pubmed: 28447407
Med Genet. 2012 Dec;24(4):262-267
pubmed: 25309043
Hum Mutat. 2015 Nov;36(11):1070-9
pubmed: 26172944
J Am Geriatr Soc. 2017 Oct;65(10):2297-2301
pubmed: 28869295
Circulation. 2014 Jul 1;130(1):27-34
pubmed: 24795390
Nature. 2011 Apr 14;472(7342):221-5
pubmed: 21346760
Nat Genet. 2013 Aug;45(8):947-50
pubmed: 23770608
PLoS One. 2015 Jul 15;10(7):e0131797
pubmed: 26176221
J Med Genet. 2018 Dec;55(12):837-846
pubmed: 30323018
Mol Genet Metab. 2013 Nov;110(3):352-61
pubmed: 24035636